Homology Medicines Inc
NASDAQ:FIXX
Income Statement
Earnings Waterfall
Homology Medicines Inc
Revenue
|
1.2m
USD
|
Operating Expenses
|
-93.3m
USD
|
Operating Income
|
-92.1m
USD
|
Other Expenses
|
-20.9m
USD
|
Net Income
|
-113m
USD
|
Income Statement
Homology Medicines Inc
Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||
Revenue |
0
N/A
|
1
N/A
|
3
+124%
|
4
+63%
|
5
+29%
|
4
-16%
|
3
-23%
|
2
-34%
|
2
-27%
|
2
+19%
|
2
+9%
|
2
+6%
|
3
+18%
|
31
+1 064%
|
33
+5%
|
34
+3%
|
34
-1%
|
5
-84%
|
4
-25%
|
3
-22%
|
3
+0%
|
3
0%
|
3
-14%
|
2
-29%
|
1
-41%
|
|
Operating Income | ||||||||||||||||||||||||||
Operating Expenses |
(30)
|
(37)
|
(46)
|
(56)
|
(65)
|
(79)
|
(92)
|
(107)
|
(112)
|
(123)
|
(131)
|
(128)
|
(133)
|
(126)
|
(123)
|
(126)
|
(130)
|
(138)
|
(134)
|
(136)
|
(136)
|
(126)
|
(128)
|
(119)
|
(93)
|
|
Selling, General & Administrative |
(8)
|
(10)
|
(13)
|
(15)
|
(17)
|
(18)
|
(19)
|
(22)
|
(22)
|
(25)
|
(28)
|
(31)
|
(33)
|
(33)
|
(34)
|
(34)
|
(37)
|
(42)
|
(41)
|
(41)
|
(38)
|
(32)
|
(32)
|
(32)
|
(31)
|
|
Research & Development |
(21)
|
(27)
|
(33)
|
(41)
|
(48)
|
(61)
|
(73)
|
(85)
|
(89)
|
(98)
|
(103)
|
(98)
|
(100)
|
(93)
|
(89)
|
(93)
|
(93)
|
(96)
|
(93)
|
(95)
|
(98)
|
(94)
|
(96)
|
(88)
|
(62)
|
|
Operating Income |
(30)
N/A
|
(36)
-20%
|
(43)
-21%
|
(52)
-21%
|
(60)
-15%
|
(74)
-24%
|
(89)
-20%
|
(105)
-18%
|
(110)
-5%
|
(121)
-10%
|
(129)
-6%
|
(126)
+2%
|
(130)
-3%
|
(95)
+27%
|
(90)
+5%
|
(92)
-3%
|
(96)
-4%
|
(132)
-38%
|
(130)
+2%
|
(132)
-2%
|
(133)
-1%
|
(123)
+8%
|
(126)
-2%
|
(117)
+7%
|
(92)
+21%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||
Interest Income Expense |
1
|
1
|
2
|
3
|
4
|
5
|
6
|
6
|
6
|
6
|
5
|
3
|
2
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
5
|
6
|
6
|
6
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
131
|
131
|
131
|
131
|
0
|
0
|
(7)
|
(1)
|
|
Total Other Income |
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(30)
N/A
|
(35)
-16%
|
(41)
-19%
|
(49)
-19%
|
(56)
-14%
|
(69)
-25%
|
(83)
-20%
|
(99)
-19%
|
(104)
-5%
|
(115)
-11%
|
(124)
-8%
|
(123)
+1%
|
(129)
-5%
|
(94)
+27%
|
(90)
+5%
|
(92)
-3%
|
(96)
-4%
|
(1)
+99%
|
2
N/A
|
1
-60%
|
1
+82%
|
(119)
N/A
|
(120)
-1%
|
(118)
+2%
|
(87)
+26%
|
|
Net Income | ||||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(30)
|
(35)
|
(41)
|
(49)
|
(56)
|
(69)
|
(83)
|
(99)
|
(104)
|
(115)
|
(124)
|
(123)
|
(129)
|
(94)
|
(90)
|
(92)
|
(96)
|
(2)
|
1
|
(0)
|
0
|
(118)
|
(120)
|
(118)
|
(87)
|
|
Equity Earnings Affiliates |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(2)
|
(4)
|
(5)
|
(8)
|
(12)
|
(13)
|
(26)
|
|
Net Income (Common) |
(30)
N/A
|
(35)
-16%
|
(41)
-19%
|
(49)
-19%
|
(56)
-14%
|
(69)
-25%
|
(83)
-20%
|
(99)
-19%
|
(104)
-5%
|
(115)
-11%
|
(124)
-8%
|
(123)
+1%
|
(129)
-5%
|
(94)
+27%
|
(90)
+5%
|
(92)
-3%
|
(96)
-4%
|
(3)
+97%
|
(1)
+55%
|
(4)
-267%
|
(5)
-17%
|
(126)
-2 414%
|
(132)
-5%
|
(131)
+1%
|
(113)
+14%
|
|
EPS (Diluted) |
-0.89
N/A
|
-0.92
-3%
|
-1.11
-21%
|
-1.3
-17%
|
-1.95
-50%
|
-1.87
+4%
|
-1.92
-3%
|
-2.24
-17%
|
-2.47
-10%
|
-2.55
-3%
|
-2.75
-8%
|
-2.73
+1%
|
-2.8
-3%
|
-1.87
+33%
|
-1.58
+16%
|
-1.61
-2%
|
-1.73
-7%
|
-0.04
+98%
|
-0.02
+50%
|
-0.07
-250%
|
-0.09
-29%
|
-2.2
-2 344%
|
-2.3
-5%
|
-2.28
+1%
|
-1.95
+14%
|